3-methyl-benzoic acid-(2-hydroxy-ethylamide) | 778623-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-benzoic acid-(2-hydroxy-ethylamide)
• 英文别名: 3-Methyl-benzoesaeure-(2-hydroxy-aethylamid)；N-(2-hydroxyethyl)-3-methylbenzamide
• CAS: 778623-19-1
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD01217157
• 分子量: 179.219
• InChiKey: DSXVTSRXHLBTKX-UHFFFAOYSA-N

物化性质

• 熔点：
  63-64 °C
• 沸点：
  208-209 °C(Press: 2 Torr)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-benzoic acid-(2-hydroxy-ethylamide) 在 三苯基膦 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以99%的产率得到2-(m-tolyl)-4,5-dihydrooxazole
  参考文献：
  名称：

  以PPh3-DDQ为脱水剂方便合成2-恶唑啉和2-苯并恶唑

  摘要：

  用三苯基膦-2,3-二氯-5,6-二氰基苯并醌（PPh 3 -DDQ）作为脱水和活化试剂分别从酰基氨基醇和酰基氨基苯酚分别以高收率合成了2-恶唑啉和2-苯并恶唑。该合成在中性条件下完成。

  DOI：

  10.1002/cjoc.201190190
• 作为产物：
  描述：

  C.I.酸性橙108 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.25h， 以53%的产率得到3-methyl-benzoic acid-(2-hydroxy-ethylamide)
  参考文献：
  名称：

  Acetamides and benzamides that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）化合物的组合物用于治疗性功能障碍。

  公开号：

  US20030229094A1

文献信息

• The α-Effect in Hydrazinolysis of 4-Chloro-2-Nitrophenyl X-Substituted-Benzoates: Effect of Substituent X on Reaction Mechanism and the α-Effect
  作者：Min-Young Kim、Tae-Eun Kim、Jieun Lee、Ik-Hwan Um

  DOI：10.5012/bkcs.2014.35.8.2271

  日期：2014.8.20

  Second-order rate constants ($k_N$) have been measured spectrophotometrically for the reaction of 4-chloro-2-nitrophenyl X-substituted-benzoates (6a-6h) with a series of primary amines including hydrazine in 80 mol % $H_2O$/20 mol % DMSO at $25.0^\circ}C$. The Br$\o}$nsted-type plot for the reaction of 4-chloro-2-nitrophenyl benzoate (6d) is linear with $\beta}_nuc}$ = 0.74 when hydrazine is excluded from the correlation. Such a linear Br$\o}$nsted-type plot is typical for reactions reported previously to proceed through a stepwise mechanism in which expulsion of the leaving group occurs in the rate-determining step (RDS). The Hammett plots for the reactions of 6a-6h with hydrazine and glycylglycine are nonlinear. In contrast, the Yukawa-Tsuno plots exhibit excellent linear correlations with $\rho}_X$ = 1.29-1.45 and r = 0.53-0.56, indicating that the nonlinear Hammett plots are not due to a change in RDS but are caused by resonance stabilization of the substrates possessing an electron-donating group (EDG). Hydrazine is ca. 47-93 times more reactive than similarly basic glycylglycine toward 6a-6h (e.g., the $\alpha}$-effect). The $\alpha}$-effect increases as the substituent X in the benzoyl moiety becomes a stronger electron-withdrawing group (EWG), indicating that destabilization of the ground state (GS) of hydrazine through the repulsion between the nonbonding electron pairs on the two N atoms is not solely responsible for the substituent-dependent $\alpha}$-effect. Stabilization of transition state (TS) through five-membered cyclic TSs, which would increase the electrophilicity of the reaction center or the nucleofugality of the leaving group, contributes to the $\alpha}$-effect observed in this study.

  二次速率常数（$k_N$）已通过分光光度法测定，用于4-氯-2-硝基苯基X取代苯甲酸酯（6a-6h）与一系列伯胺（包括80摩尔% $H_2O$/20摩尔% DMSO中的25.0°C下的联氨）的反应。当联氨被排除在相关性之外时，4-氯-2-硝基苯基苯甲酸酯（6d）反应的Br$\o}$nsted型图是线性的，$\beta}_nuc}$ = 0.74。这种线性Br$\o}$nsted型图是典型的反应，先前报道这些反应通过逐步机制进行，其中离去基团的排出发生在速率决定步骤（RDS）中。6a-6h与联氨和甘氨酰甘氨酸反应的Hammett图是非线性的。相比之下，Yukawa-Tsuno图显示出极佳的线性相关性，$\rho}_X$ = 1.29-1.45，r = 0.53-0.56，表明非线性Hammett图并非由于RDS的变化，而是由于具有供电子基团（EDG）的底物的共振稳定化所导致。联氨对6a-6h的反应性大约是同样碱性的甘氨酰甘氨酸的47-93倍（例如，$\alpha}$效应）。随着苯甲酰基中取代基X成为更强的吸电子基团（EWG），$\alpha}$效应增加，表明通过两个N原子上的非键电子对之间的排斥来破坏联氨的基态（GS）并不是唯一导致取代基依赖的$\alpha}$效应的原因。通过五元环过渡态（TS）的稳定化，这将增加反应中心的亲电性或离去基团的离核性，有助于在本研究中观察到的$\alpha}$效应。
• A Mild and Regioselective Route to Functionalized Quinazolines
  作者：Tracy M. M. Maiden、Stephen Swanson、Panayiotis A. Procopiou、Joseph P. A. Harrity

  DOI：10.1002/chem.201502891

  日期：2015.10.5

  A Rh‐catalyzed ortho‐amidation cyclocondensation sequence gave a range of 4‐aminoquinazolines in high yield. The method features a remarkably mild C(sp2)H activation step and can be exploited to rapidly access compounds with established biological activity.

  Rh催化的邻酰胺化环缩合序列可高产率地得到一系列的4-氨基喹唑啉。该方法具有非常温和的C（sp 2）H活化步骤，可用于快速访问具有确定生物学活性的化合物。
• ORGANIC COMPOUNDS
  申请人：Lizos Dimitrios

  公开号：US20100204235A1

  公开（公告）日：2010-08-12

  Compounds of formula I in free or salt or solvate form, where R 1 , R 2 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK- 5 and/or ALK- 4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，以自由形式、盐形式或溶剂合物形式存在，其中R1、R2和R5的含义如规范中所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Oxazolinyl-Assisted Ru(II)-Catalyzed C–H Allylation with Allyl Alcohols and Synthesis of 4-Methyleneisochroman-1-ones
  作者：Diksha Singh、Gangam Srikanth Kumar、Manmohan Kapur

  DOI：10.1021/acs.joc.9b01536

  日期：2019.10.18

  for C-H allylation of aryl oxazolines using allylic alcohols as the coupling partner. The present transformation unravels the unusual reactivity of allylic alcohols in the synthesis of 4-methyleneisochroman-1-ones and C-H-allylated products. A complete switch in the product selectivity was observed with substrate control and tuning the reaction conditions. The approach employs allyl alcohols as an efficient

  我们在本文中报道了使用烯丙醇作为偶联伙伴的芳基恶唑啉的CH烯丙基化的钌催化的，恶唑啉定向的策略。本转化揭示了在4-亚甲基异色满-1-酮和CH-烯丙基化产物的合成中烯丙基醇的异常反应性。通过底物控制和调节反应条件，观察到产物选择性的完全改变。该方法采用烯丙醇作为预活化的烯丙基化剂的有效替代品，以高度选择性的方式获得各种产品。
• [EN] C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉ INHIBITEUR DE TYROSINE KINASE C-ABL, MODES DE RÉALISATION, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：US HEALTH

  公开号：WO2019173761A1

  公开（公告）日：2019-09-12

  Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c- Abl inhibitory compound embodiments.

  本文披露了一种抑制c-Abl酪氨酸激酶（本文中也称为"c-Abl"）的化合物实施例。本文描述的这些化合物实施例是新颖的c-Abl抑制剂，可以结合到c-Abl的一个变构位点，并在各种途径中抑制其活性。这些化合物实施例还能够穿过血脑屏障，因此在抑制影响大脑途径和/或蛋白质的c-Abl活性方面是有用的。本文描述的这些化合物实施例是治疗涉及c-Abl的疾病的有效治疗剂，如癌症、运动神经元疾病和神经退行性疾病。本文还披露了制备和使用c-Abl抑制化合物实施例的方法实施例。